BLT up over 10% today. Been stuck around 30c for a while so hopefully the ascension continues.
Printable View
BLT up over 10% today. Been stuck around 30c for a while so hopefully the ascension continues.
BLT 35c. Did you get to the BioBus stop in time KW?:)
Andrew Kroger's buying must be seen as positive.
BLT up 20% plus in 2 days. Presentation out today.
BLT hovering around 40c
BLT up re 13% to 47c today .:)
BLT:ASX on a bit of a roll here and maybe a break-out day today.
There's a degree of excitement here as the Calimmune HIV trial must be beginning to see some results from the first cohort (4 only). This trial is in 3 cohorts of 4 patients each, with the first patient treated in July. I have to admire the patients that put themselves up for this - entering the programme will generally imply they've been off meds for 6 weeks, which carries a high degree of risk in itself.
While Calimmune is a licensee arrangement only, there is a lot of eyes on this work re potential for ddRNAI therapy. Additionally, the Benitec-owned therapy for Hep C should enter phaseI/IIa trials soon, so there is a double shot at proving the technology platform in the next 6-18 months.
My best spec hope for a 10-bagger at present - although I'm only just heading back to "break-even" at these levels, having bought my initial stake too early!
Hi Lizard thanks for sharing again re BLT. I like "Best spec for a 10 bagger" im nearly a 1 bagger in little over a month; no skill involved with my timing mainly luck! very strong support atm@ 54.5c. cheers DJV
Roger Montgomery has given CGS a big write up:
http://rogermontgomery.com/new-inves...opportunities/
"CogState is capitalised at $34.7 million, has no debt, and
cash reserves and short term investments of $3.1 million in
the September quarter. The enterprise value, therefore,
is $31.6 million. Based on trailing sales of $12.6 million,
the enterprise value to sales ratio is 2.5 times ($31.6
million/$12.6 million).
To put that in perspective, Resmed and Cochlear usually
trade on an EV/sales multiple of 4-5 times; less-established
biotechs in the loss-making phase often trade around 3
times sales, and low-growth biotechs can have an EV/
sales of 0.5 to 1 times. High-growth biotechs trading on
an EV / sales multiple closer to 2 times sales are often
viewed as undervalued, on this simplistic metric.
CogState has plenty of upside potential
and arguably less risk than many emerging biotechs,
given it has a developed product, established revenue
base, and is on the cusp of faster commercialisation of its
newer products. "
Comments on a few biotech stocks:
http://www.thebull.com.au/premium/a/...re-prices.html
Interesting one. The email response from the company, posted on HC was interesting regarding the "re-injury" occurring as a result of application of silver compound - which affected the re-growing skin cells in the same way it would affect bacterial growth, I think? However, the admission seemed also an admission of sloppiness in procedure?
I took a good look at AVH today (think I once owned CCE for a short, break-even trade), and felt the technology was hugely promising, but the management delivery just doesn't seem to be quite there. Could be critical for a company that will likely need more cash. I passed, but think it is still worth watching.
What about nanosonics, anyone done research into this company?
ASX code is NAN.
flogged the rest of my NEU shares @12.5c and have applied for a greater figure @11.5c placement. Current s/p hitting 14c!!!!. Pretty crazy. Some very clever spruikers on H/C help the fervor. Have held for years.
And back down to 12.7c lol